menu
    • menu
    [{"orgOrder":0,"company":"Cellivery","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"iCP-NI","moa":"TNF-alpha receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Cellivery","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cellivery \/ LabCorp","highestDevelopmentStatusID":"6","companyTruncated":"Cellivery \/ LabCorp"},{"orgOrder":0,"company":"Cellivery","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"iCP-NI","moa":"TNF-alpha receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cellivery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellivery \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cellivery \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellivery

    Menu

    Cellivery

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellivery

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Cellivery

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iCP-NI

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Labcorp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects

                            Details : ICP-NI is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            February 23, 2023

                            Lead Product(s) : iCP-NI

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Labcorp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellivery

                            South Korea arrow
                            OTS 2025
                            Not Confirmed

                            Cellivery

                            South Korea arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iCP-NI

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellivery, iCP-NI 'Corona 19' Primate Treatment Efficacy Verification Begins

                            Details : The new drug iCP-NI begins to verify the efficacy of treatment for the treatment of acute pneumonia and severe sepsis caused by corona19.

                            Product Name : iCP-NI

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            March 27, 2020

                            Lead Product(s) : iCP-NI

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth